Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Short Interest Up 79.1% in October

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) was the recipient of a significant growth in short interest during the month of October. As of October 15th, there was short interest totaling 108,900 shares, a growth of 79.1% from the September 30th total of 60,800 shares. Based on an average daily trading volume, of 514,300 shares, the days-to-cover ratio is presently 0.2 days. Currently, 6.2% of the company’s shares are sold short. Currently, 6.2% of the company’s shares are sold short. Based on an average daily trading volume, of 514,300 shares, the days-to-cover ratio is presently 0.2 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alaunos Therapeutics in a research note on Tuesday, October 14th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Alaunos Therapeutics currently has an average rating of “Sell”.

Alaunos Therapeutics Trading Up 1.5%

Alaunos Therapeutics stock opened at $2.72 on Friday. The firm has a 50-day moving average of $2.61 and a 200-day moving average of $2.95. The firm has a market cap of $6.31 million, a P/E ratio of -1.11 and a beta of -0.84. Alaunos Therapeutics has a 1-year low of $1.31 and a 1-year high of $6.20.

Alaunos Therapeutics (NASDAQ:TCRT) last posted its earnings results on Thursday, August 14th. The company reported ($0.63) earnings per share for the quarter, topping analysts’ consensus estimates of ($5.33) by $4.70.

About Alaunos Therapeutics

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers.